


**Amendments to the Claims:**

This listing of claims will replace all prior versions and listings of claims in the application.

**Listing of Claims:**

Claim 1 (currently amended): A quinazoline derivative of the formula I:



1

wherein:

**each of R<sup>1</sup> and R<sup>2</sup>,** which may be the same or different, is selected from hydrogen, carboxy, cyano, formyl, (1-3C)alkyl, (2-3C)alkanoyl, (1-3C)alkoxycarbonyl, carbamoyl, N-(1-3C)alkylcarbamoyl and N, N-di[(1-3C)alkyl]carbamoyl;

**each of R<sup>1a</sup> and R<sup>2a</sup>,** which may be the same or different, is selected from hydrogen and (1-3C)alkyl;

**each of R<sup>3</sup> and R<sup>4</sup>,** which may be the same or different, is selected from hydrogen, (1-3C)alkyl and (2-4C) alkenyl; and,

wherein any CH or CH<sub>2</sub> or CH<sub>3</sub> within any of R<sup>1</sup>, R<sup>1a</sup>, R<sup>2</sup>, R<sup>2a</sup>, R<sup>3</sup> and R<sup>4</sup> optionally bears on each said CH or CH<sub>2</sub> or CH<sub>3</sub> one or more halogeno substituents or a substituent selected from hydroxy, cyano, and (1-3C)alkoxy, amino, (2-3C)alkanoyl, (1-3C)alkylamino and di [(1-3C)alkyl]amine;

X is selected from hydrogen, halogeno, (1-4C)alkyl, (1-4C)alkoxy, (2-4C)alkenyl and (2-4C)alkynyl;

each  $\mathbf{R}^5$ , which may be the same or different, is selected from halogeno, hydroxy, (1-4C)alkyl, (1-4C)alkoxy, (2-4C)alkenyl and (2-4C)alkynyl;

$\mathbf{Y}$  is selected from a direct bond, O, S,  $\text{OC}(\mathbf{R}^7)_2$ ,  $\text{SC}(\mathbf{R}^7)_2$ ,  $\text{SO}_2$ ,  $\text{N}(\mathbf{R}^7)$ , CO and  $\text{N}(\mathbf{R}^7)\text{C}(\mathbf{R}^7)_2$  wherein each  $\mathbf{R}^7$  is, independently, hydrogen or (1-6C)alkyl;

$\mathbf{Q}^1$  is selected from phenyl, pyridyl, pyrazinyl, 1,3-thiazolyl, 1H-imidazolyl, 1H-pyrazolyl, 1,3-oxazolyl and isoxazolyl, and

wherein  $\mathbf{Q}^1$  optionally bears one or more substituents, which may be the same or different, selected from halogeno, cyano, nitro, hydroxy, amino, carboxy, carbamoyl, sulfamoyl, formyl, mercapto, (1-6C)alkyl, (2-8C)alkenyl, (2-8C)alkynyl, (1-6C)alkoxy, (2-6C)alkenyloxy, (2-6C)alkynyloxy, (1-6C)alkylthio, (1-6C)alkylsulfinyl, (1-6C)alkylsulfonyl, (1-6C)alkylamino, di-[(1-6C)alkyl]amino, (1-6C)alkoxycarbonyl, N-(1-6C)alkylcarbamoyl, N,N-di-[(1-6C)alkyl]carbamoyl, (2-6C)alkanoyl, (2-6C)alkanoyloxy, (2-6C)alkanoylamino, N-(1-6C)alkyl-(2-6C)alkanoylamino, (3-6C)alkenoylamino, N-(1-6C)alkyl-(3-6C)alkenoylamino, (3-6C)alkynoylamino, N-(1-6C)alkyl-(3-6C)alkynoylamino, N-(1-6C)alkylsulfamoyl, N,N-di-[(1-6C)alkyl]sulfamoyl, (1-6C)alkanesulfonylamino, and N-(1-6C)alkyl-(1-6C)alkanesulfonylamino, or from a group of the formula: - $\mathbf{X}^1-\mathbf{R}^8$ , wherein

$\mathbf{X}^1$  is a direct bond or is selected from O, CO and  $\text{N}(\mathbf{R}^9)$ , wherein:

$\mathbf{R}^9$  is hydrogen or (1-6C)alkyl, and

$\mathbf{R}^8$  is halogeno-(1-6C)alkyl, hydroxy-(1-6C)alkyl, carboxy-(1-6C)alkyl, (1-6C)alkoxy-(1-6C)alkyl, cyano-(1-6C)alkyl, amino-(1-6C)alkyl, N-(1-6C)alkylamino-(1-6C)alkyl, N,N-di-[(1-6C)alkyl]amino-(1-6C)alkyl, (2-6C)alkanoylamino-(1-6C)alkyl, (1-6C)alkoxycarbonylamino-(1-6C)alkyl, carbamoyl-(1-6C)alkyl, N-(1-6C)alkylcarbamoyl-(1-6C)alkyl, N,N-di-[(1-6C)alkyl]carbamoyl-(1-6C)alkyl, (2-6C)alkanoyl-(1-6C)alkyl or (1-6C)alkoxycarbonyl-(1-6C)alkyl, and

wherein any  $\text{CH}_2$  or  $\text{CH}_3$  within a substituent on  $\mathbf{Q}^1$  optionally bears on each said  $\text{CH}_2$  or  $\text{CH}_3$  one or more halogeno or (1-6C)alkyl substituents or a substituent selected from hydroxy, cyano, amino, (1-4C)alkoxy, (1-4C)alkylamino and di-[(1-4C)alkyl]amino;

$\mathbf{R}^6$  is selected from hydrogen, (1-6C)alkoxy, (2-6C)alkenyloxy and (2-6C)alkynyloxy, and

wherein any CH<sub>2</sub> or CH<sub>3</sub> group within a R<sup>6</sup> substituent optionally bears on each said CH<sub>2</sub> or CH<sub>3</sub> group one or more halogeno or (1-6C)alkyl substituents, or a substituent selected from hydroxy and (1-6C)alkoxy;  
n is 0, 1, 2 or 3;  
or a pharmaceutically acceptable salt thereof.

Claim 2 (currently amended): A-The quinazoline derivative of the formula I as defined in claim 1, wherein R<sup>1</sup> is selected from hydrogen, methyl and ethyl; R<sup>2</sup> is selected from hydrogen, carboxy, cyano, methyl, ethyl, acetyl, methoxycarbonyl, carbamoyl, N-methylcarbamoyl and N,N-di-methylcarbamoyl; and R<sup>1a</sup> and R<sup>2a</sup> are each hydrogen.

Claim 3 (currently amended): A-The quinazoline derivative of the formula I as defined in claim 1, wherein R<sup>2</sup> is selected from hydrogen, methyl and ethyl; R<sup>1</sup> is selected from hydrogen, carboxy, cyano, methyl, ethyl, acetyl, methoxycarbonyl, carbamoyl, N-methylcarbamoyl and N,N-di-methylcarbamoyl; and R<sup>1a</sup> and R<sup>2a</sup> are each hydrogen.

Claim 4 (currently amended): A-The quinazoline derivative of the formula I as defined in claim 1, wherein R<sup>1</sup> and R<sup>1a</sup> are each hydrogen; R<sup>2</sup> is selected from hydrogen, carboxy, cyano, methyl, ethyl, acetyl, methoxycarbonyl, carbamoyl, N-methylcarbamoyl and N,N-di-methylcarbamoyl; and R<sup>2a</sup> is selected from hydrogen and (1-3C)alkyl.

Claim 5 (currently amended): A-The quinazoline derivative of the formula I as defined in claim 1, wherein R<sup>2</sup> and R<sup>2a</sup> are each hydrogen; R<sup>1</sup> is selected from hydrogen, carboxy, cyano, methyl, ethyl, acetyl, methoxycarbonyl, carbamoyl, N-methylcarbamoyl and N,N-di-methylcarbamoyl; and R<sup>1a</sup> is selected from hydrogen and (1-3C)alkyl.

Claim 6 (currently amended): A-The quinazoline derivative of the formula I as defined in claim 1, wherein R<sup>1</sup> is methyl; and R<sup>2</sup>, R<sup>1a</sup> and R<sup>2a</sup> are each hydrogen.

Claim 7 (currently amended): A-The quinazoline derivative of the formula I as defined in claim 1, wherein R<sup>2</sup> is methyl; and R<sup>1</sup>, R<sup>1a</sup> and R<sup>2a</sup> are each hydrogen.

Claim 8 (currently amended): A-The quinazoline derivative of the formula I as defined in claim 1, wherein R<sup>1</sup> and R<sup>1a</sup> are each methyl; and R<sup>2</sup> and R<sup>2a</sup> are each hydrogen.

Claim 9 (currently amended): A-The quinazoline derivative of the formula I as defined in claim 1, wherein R<sup>2</sup> and R<sup>2a</sup> are each methyl; and R<sup>1</sup> and R<sup>1a</sup> are each hydrogen.

Claim 10 (currently amended): A-The quinazoline derivative of the formula I as defined in claim 1, wherein each of R<sup>3</sup> and R<sup>4</sup>, which may be the same or different, is selected from (1-3C)alkyl, wherein any CH or CH<sub>2</sub> or CH<sub>3</sub> within any of R<sup>3</sup> and R<sup>4</sup> optionally bears on each said CH or CH<sub>2</sub> or CH<sub>3</sub> one or more substituents selected from hydroxy and (1-3C)alkoxy.

Claim 11 (currently amended): A-The quinazoline derivative of the formula I as defined in claim 1, wherein each of R<sup>3</sup> and R<sup>4</sup>, which may be the same or different, is selected from hydrogen, methyl, ethyl, propenyl, 2-methoxyethyl and 2-hydroxyethyl.

Claim 12 (currently amended): A-The quinazoline derivative of the formula I as defined in claim 11, wherein each of R<sup>3</sup> and R<sup>4</sup>, which may be the same or different, is selected from methyl, ethyl, propenyl, 2-methoxyethyl and 2-hydroxyethyl.

Claim 13 (currently amended): A-The quinazoline derivative of the formula I as defined in claim 11, wherein R<sup>3</sup> is methyl and R<sup>4</sup> is selected from methyl, ethyl, 2-hydroxyethyl, 2-methoxyethyl and propenyl.

| Claim 14 (currently amended): ~~A-The~~ quinazoline derivative of ~~the~~-formula I as defined in claim 10, wherein R<sup>3</sup> and R<sup>4</sup> are each methyl.

| Claim 15 (currently amended): ~~A-The~~ quinazoline derivative of ~~the~~-formula I as defined in claim 10, wherein R<sup>3</sup> is ethyl and R<sup>4</sup> is 2-hydroxyethyl.

| Claim 16 (currently amended): ~~A-The~~ quinazoline derivative of ~~the~~-formula I as defined in claim 1, wherein X is selected from hydrogen, halogeno, (1-4C)alkyl and (1-4C)alkoxy.

| Claim 17 (currently amended): ~~A-The~~ quinazoline derivative of ~~the~~-formula I as defined in claim 16, wherein X is selected from hydrogen, fluoro, chloro, methyl and methoxy.

| Claim 18 (currently amended): ~~A-The~~ quinazoline derivative of ~~the~~-formula I as defined in claim 16, wherein X is selected from methyl and chloro.

| Claim 19 (currently amended): ~~A-The~~ quinazoline derivative of ~~the~~-formula I as defined in claim 18, wherein X is chloro.

| Claim 20 (currently amended): ~~A-The~~ quinazoline derivative of ~~the~~-formula I as defined in claim 18, wherein X is methyl.

| Claim 21 (currently amended): ~~A-The~~ quinazoline derivative of ~~the~~-formula I as defined in claim 1, wherein Y is selected from O, S and OC(R<sup>7</sup>)<sub>2</sub> wherein each R<sup>7</sup> is, independently, hydrogen or (1-4C)alkyl.

| Claim 22 (currently amended): ~~A-The~~ quinazoline derivative of ~~the~~-formula I as defined in claim 21, wherein Y is selected from O, S and OCH<sub>2</sub>.

| Claim 23 (currently amended): A-The quinazoline derivative of the formula I as defined in claim 21, wherein Y is O.

| Claim 24 (currently amended): A-The quinazoline derivative of the formula I as defined in claim 21, wherein Y is S.

| Claim 25 (currently amended): A-The quinazoline derivative of the formula I as defined in claim 21, wherein Y is OCH<sub>2</sub>.

| Claim 26 (currently amended): A-The quinazoline derivative of the formula I as defined in claim 1, wherein n is 0.

| Claim 27 (currently amended): A-The quinazoline derivative of the formula I as defined in claim 1, wherein Q<sup>1</sup> is selected from phenyl, 2-pyridyl, 2-pyrazinyl, 1,3-thiazol-4-yl, 1,3-thiazol-5-yl, 1H-imidazol-2-yl and isoxazol-3-yl, and wherein Q<sup>1</sup> optionally bears one or more substituents, which may be the same or different, as defined in claim I.

| Claim 28 (currently amended): A-The quinazoline derivative of the formula I as defined in claim 27, wherein Q<sup>1</sup> is selected from phenyl, 2-pyridyl, 2-pyrazinyl, 1,3-thiazol-4-yl, 1,3-thiazol-5-yl, 1H-imidazol-2-yl and 3-isoxazolyl, and wherein Q<sup>1</sup> optionally bears one or more substituents, which may be the same or different, selected from fluoro and (1-4C)alkyl.

| Claim 29 (currently amended): A-The quinazoline derivative of the formula I as defined in claim 27, wherein Q<sup>1</sup> is selected from 3-fluorophenyl, 2-pyridyl, 2-pyrazinyl, 1-methyl-1H-imidazol-2-yl, 1,3-thiazol-4-yl, 1,3-thiazol-5-yl and 5-methyl-3-isoxazolyl.

| Claim 30 (currently amended): A-The quinazoline derivative of the formula I as defined in claim 1, wherein R<sup>6</sup> is hydrogen.

| Claim 31 (currently amended): A-The quinazoline derivative as defined in claim 1 selected from the following:

4-(3-Chloro-4-(2-pyridylmethoxy)anilino)-5-(2-dimethylaminoethoxy)quinazoline;  
4-(3-Chloro-4-(2-pyridylmethoxy)anilino)-5-(2-dimethylamino-1-methylethoxy)quinazoline;  
4-(3-Chloro-4-(1-methyl-1*H*-imidazol-2-ylthio)anilino)-5-(2-dimethylaminoethoxy)quinazoline;  
4-(3-Chloro-4-(1-methyl-1*H*-imidazol-2-ylthio)anilino)-5-(2-dimethylamino-2-methylethoxy)quinazoline;  
4-(4-(3-Fluorobenzoyloxy)anilino)-5-(2-dimethylaminoethoxy)quinazoline;  
4-(4-(3-Fluorobenzoyloxy)anilino)-5-(2-dimethylamino-1-methylethoxy)quinazoline;  
4-(3-Chloro-4-(2-pyrazinylmethoxy)anilino)-5-(2-dimethylaminoethoxy)quinazoline;  
4-(3-Chloro-4-(2-pyrazinylmethoxy)anilino)-5-(2-dimethylamino-1-methylethoxy)quinazoline;  
4-(3-Chloro-4-(5-methylisoxazol-3-ylmethoxy)anilino)-5-(2-dimethylaminoethoxy)quinazoline;  
4-(3-Chloro-4-(5-methylisoxazol-3-ylmethoxy)anilino)-5-(2-dimethylamino-1-methylethoxy)quinazoline;  
4-(3-Chloro-4-(3-fluorobenzoyloxy)anilino)-5-(2-(N-ethyl-N-methylamino)ethoxy)quinazoline;  
4-(3-Chloro-4-(3-fluorobenzoyloxy)anilino)-5-(2-dimethylaminoethoxy)quinazoline;  
4-(3-Chloro-4-(3-fluorobenzoyloxy)anilino)-5-[2-(N-(2-hydroxyethyl)-N-methylamino)ethoxy]quinazoline;  
4-(3-Chloro-4-(2-pyridylmethoxy)anilino)-5-(2-(N-ethyl-N-methylamino)ethoxy)quinazoline;  
4-(3-Chloro-4-(2-pyridylmethoxy)anilino)-5-(2-(N-(2-hydroxyethyl)-N-methylamino)ethoxy)quinazoline;  
4-(3-Chloro-4-(3-fluorobenzoyloxy)anilino)-5-(2-dimethylamino-2-methylethoxy)quinazoline;  
4-(3-Chloro-4-(2-pyridylmethoxy)anilino)-5-(2-dimethylamino-2-methylethoxy)quinazoline;  
*N*-[3-Chloro-4-(1,3-thiazol-4-ylmethoxy)phenyl]-5-[2-(dimethylamino)ethoxy]quinazolin-4-amine;  
*N*-[3-Chloro-4-(pyridin-2-yloxy)phenyl]-5-[2-(dimethylamino)ethoxy]quinazolin-4-amine;  
*N*-[3-Chloro-4-(pyrazin-2-ylmethoxy)phenyl]-5-[(1*S*)-2-(dimethylamino)-1-methylethoxy]quinazolin-4-amine;

N- {3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-[(1*S*)-2-(dimethylamino)-1-methylethoxy]quinazolin-4-amine;

N-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[(1*R*)-2-(dimethylamino)-1-methylethoxy]quinazolin-4-amine;

N-[3-Chloro-4-(1,3-thiazol-4-ylmethoxy)phenyl]-5-[(1*R*)-2-(dimethylamino)-1-methylethoxy]quinazolin-4-amine;

N-[3-Chloro-4-(pyrazin-2-ylmethoxy)phenyl]-5-[(1*R*)-2-(dimethylamino)-1-methylethoxy]quinazolin-4-amine;

N- {3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-[(1*R*)-2-(dimethylamino)-1-methylethoxy]quinazolin-4-amine;

N-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[2-(dimethylamino)-2-methylpropoxy]quinazolin-4-amine;

N-[3-Chloro-4-(1,3-thiazol-4-ylmethoxy)phenyl]-5-[2-(dimethylamino)-2-methylpropoxy]quinazolin-4-amine;

N- {3-Chloro-4-[(5-methylisoxazol-3-yl)methoxy]phenyl}-5-[2-(dimethylamino)-2-methylpropoxy]quinazolin-4-amine;

5-[2-(Dimethylamino)ethoxy]-N-[3-methyl-4-(pyridin-2-ylmethoxy)phenyl]quinazolin-4-amine;

5-[2-(Dimethylamino)ethoxy]-N-[3-methyl-4-(1,3-thiazol-4-ylmethoxy)phenyl]quinazolin-4-amine;

5-[2-(Dimethylamino)ethoxy]-N- {3-methyl-4-[(5-methylisoxazol-3-yl)methoxy]phenyl}quinazolin-4-amine;

5-[(1*R*)-2-(Dimethylamino)-1-methylethoxy]-N-[3-methyl-4-(pyridin-2-ylmethoxy)phenyl]quinazolin-4-amine;

5-[(1*R*)-2-(Dimethylamino)-1-methylethoxy]-N-[3-methyl-4-(pyrazin-2-ylmethoxy)phenyl]quinazolin-4-amine;

5-[(1*R*)-2-(dimethylamino)Dimethylamino-1-methylethoxy]-N-[3-methyl-4-(1,3-thiazol-4-ylmethoxy)phenyl]quinazolin-4-amine;

5-[(1*R*)-2-(Dimethylamino)-1-methylethoxy]-N- {3-methyl-4-[(5-methylisoxazol-3-yl)methoxy]phenyl}quinazolin-4-amine;

| 5-[2-(dimethylamino)dimethylamino)-2-methylpropoxy]-*N*-[3-methyl-4-(1,3-thiazol-4-ylmethoxy)phenyl]quinazolin-4-amine;

5-[2-(Dimethylamino)ethoxy]-*N*-{3-methoxy-4-[(5-methylisoxazol-3-yl)methoxy]phenyl}quinazolin-4-amine;

5-[2-(Dimethylamino)ethoxy]-*N*-[3-methoxy-4-(pyrazin-2-ylmethoxy)phenyl]quinazolin-4-amine;

5-[2-(Dimethylamino)ethoxy]-*N*-[3-fluoro-4-(1,3-thiazol-5-ylmethoxy)phenyl]quinazolin-4-amine;

*N*-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[(1*S*)-2-(dimethylamino)-1-methylethoxy]quinazolin-4-amine;

*N*-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[(2*S*)-2-(dimethylamino)propyl]oxy]quinazolin-4-amine;

*N*-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[(2*R*)-2-(dimethylamino)propyl]oxy]quinazolin-4-amine;

5-{2-[Allyl(methyl)amino]ethoxy}-*N*-[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]quinazolin-4-amine;

2-[{2-[(4-([3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]amino)quinazolin-5-yl)oxy]ethyl}(ethyl)amino]ethanol;

*N*-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[(1*S*)-2-[(2-methoxyethyl)(methyl)amino]-1-methylethoxy]quinazolin-4-amine;

*N*-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[(1*R*)-2-[ethyl(methyl)amino]-1-methylethoxy]quinazolin-4-amine;

5-[(1*R*)-2-[Allyl(methyl)amino]-1-methylethoxy]-*N*-[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]quinazolin-4-amine;

*N*-[(1*S*)-2-[Allyl(methyl)amino]-1-methylethoxy]-*N*-[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]quinazolin-4-amine;

*N*-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-[(2*S*)-2-(dimethylamino)propyl]oxy]quinazolin-4-amine;

*N*-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-5-{{(2*R*)-2-(dimethylamino)propyl}oxy}-quinazolin-4-amine;

*N*-{3-Chloro-4-[(1-methyl-1*H*-imidazol-2-yl)thio]phenyl}-5-{{(2*S*)-2-(dimethylamino)propyl}oxy}quinazolin-4-amine;

*N*-{3-Chloro-4-[(1-methyl-1*H*-imidazol-2-yl)thio]phenyl}-5-{{(2*R*)-2-(dimethylamino)propyl}oxy}quinazolin-4-amine;

*N*-{3-Chloro-4-[(1-methyl-1*H*-imidazol-2-yl)thio]phenyl}-5-[(1*R*)-2-(dimethylamino)-1-methylethoxy]quinazolin-4-amine;

5-[2-(Dimethylamino)-1-methylethoxy]-*N*-(3-methoxy-4-phenoxyphenyl)quinazolin-4-amine;

5-[2-(Dimethylamino)-1-methylethoxy]-*N*-(3-methoxy-4-phenoxyphenyl)quinazolin-4-amine;  
and

*N*-[3-Chloro-4-(pyridin-2-ylmethoxy)phenyl]-5-[2-(dimethylamino)-1,1-dimethylethoxy]quinazolin-4-amine;


or a pharmaceutically acceptable salt thereof.

Claim 32 (original): A pharmaceutical composition which comprises a quinazoline derivative of the formula I, or a pharmaceutically acceptable salt thereof, as defined in claim 1 in association with a pharmaceutically-acceptable diluent or carrier.


Claims 33-36 (cancelled).

Claim 37 (currently amended): A process for the preparation of preparing a quinazoline derivative of the formula I, or a pharmaceutically acceptable salt thereof, as defined in claim 1 which comprises:

(a) the reaction reacting, conveniently optionally in the presence of a suitable base, of a quinazoline of the formula II:




wherein R<sup>5</sup>, R<sup>6</sup>, Q<sup>1</sup>, X, Y and n are as defined in claim 1 except that any functional group is optionally protected if necessary; and L is a displaceable group, with an alcohol of the formula III:



III

wherein R<sup>1</sup>, R<sup>1a</sup>, R<sup>2</sup>, R<sup>2a</sup>, R<sup>3</sup> and R<sup>4</sup> are as defined in claim 1 except that any functional group is optionally protected if necessary; or

(b) for the preparation of these the compounds of the formula I wherein Y is OC(R<sup>7</sup>)<sub>2</sub>, SC(R<sup>7</sup>)<sub>2</sub> or N(R<sup>7</sup>)C(R<sup>7</sup>)<sub>2</sub>, the reaction reacting, conveniently optionally in the presence of a suitable base, of a quinazoline of the formula IV:




wherein Y is O, S or N(R<sup>7</sup>)<sub>2</sub> and X, R<sup>1</sup>, R<sup>1a</sup>, R<sup>2</sup>, R<sup>2a</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup> and n are as defined in claim 1 except that any functional group is optionally protected if necessary, with a compound of the formula V:



V

wherein L<sup>1</sup> is a suitable displaceable group and Q<sup>1</sup> and R<sup>7</sup> are as defined in claim 1 except that any functional group is optionally protected if necessary; or

(c) the reaction of reacting a quinazoline of the formula VI:



VI


wherein L<sup>2</sup> is a suitable displaceable group and Q<sup>1</sup>, X, Y, R<sup>1</sup>, R<sup>1a</sup>, R<sup>2</sup>, R<sup>2a</sup>, R<sup>5</sup>, R<sup>6</sup> and n are as defined in claim 1 except that any functional group is optionally protected if necessary, with an amine of the formula VII:



VII

wherein R<sup>3</sup> and R<sup>4</sup> are as defined in claim 1 except that any functional group is optionally protected if necessary; or

(d) for the preparation of those the compounds of the formula I wherein R<sup>2a</sup> is hydrogen, the reductive amination in the presence of a suitable reducing agent of the aldehyde or ketone of the formula VIII:




wherein Q<sup>1</sup>, X, Y, R<sup>1</sup>, R<sup>1a</sup>, R<sup>2</sup>, R<sup>5</sup>, R<sup>6</sup> and n are as defined in claim 1 except that any functional group is optionally protected if necessary, with an amine of the formula **VII**:



**VII**


wherein R<sup>3</sup> and R<sup>4</sup> are as defined in claim 1 except that any functional group is optionally protected if necessary; or

(e) for the preparation of these the compounds of the formula **I** wherein Y is O or N(R<sup>7</sup>) and Q<sup>1</sup> is 2-pyridyl or 4-pyridyl, the reaction reacting, in the presence of a suitable catalyst, of a quinazoline of the formula **IV**:




**IV**

wherein Y is O or N(R<sup>7</sup>) and X, R<sup>1</sup>, R<sup>1a</sup>, R<sup>2</sup>, R<sup>2a</sup>, R<sup>3</sup>, R<sup>4</sup>, R<sup>5</sup>, R<sup>6</sup> and n are as defined in claim 1 except that any functional group is optionally protected if necessary, with an amine of the formula **IVa** or of the formula **IVb**:




IVa



IVb


wherein L<sup>3</sup> is a suitable displaceable group; or

(f) reacting, conveniently optionally in the presence of a suitable phosphine and a suitable diazo compound, of a quinazoline of the formula II:



II

wherein R<sup>5</sup>, R<sup>6</sup>, Q<sup>1</sup>, X, Y and n are as defined in claim 1 except that any functional group is optionally protected if necessary, and L<sup>4</sup> is hydroxy, with an alcohol of the formula III:



III

wherein R<sup>1</sup>, R<sup>1a</sup>, R<sup>2</sup>, R<sup>2a</sup>, R<sup>3</sup> and R<sup>4</sup> are as defined in claim 1 except that any functional group is optionally protected;

and thereafter, optionally:

- (i) converting a quinazoline derivative of the formula I into another quinazoline derivative of the formula I;
- (ii) removing any protecting group that is present;
- (iii) forming a pharmaceutically acceptable salt.

Claim 38 (currently amended): A method for treating a breast tumour sensitive to inhibition of the erbB2 receptor tyrosine kinase in a warm-blooded animal in need of such treatment, which comprises administering to said the animal an effective amount of a quinazoline derivative of the formula I, or a pharmaceutically-acceptable salt thereof, as defined in claim 1.

Claim 39 (cancelled).